Thompson Medical
This article was originally published in The Tan Sheet
Executive Summary
Asks FDA in an April 15 letter to reopen the administrative record for OTC topical analgesics to include an additional double-blind, placebo- controlled clinical trial intended to support the efficacy of trolamine salicylate (Thompson Med's Aspercreme) as a topical analgesic to relieve stiffness and pain associated with arthritis. The firm submitted data in December that showed that Aspercreme provided significant improvement over placebo in arthritis relief ("The Tan Sheet" Jan. 24, p. 16). The tentative final monograph for OTC topical analgesics did not include trolamine as a monograph ingredient
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning